Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 7/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.59 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | TYK2 | P29597 | 8/20 | 0.46 |
| ▸ | JAK1 | P23458 | 7/20 | 0.46 |
| ▸ | JAK2 | O60674 | 5/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | ULK1 | O75385 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1292918 | 0.87 | PTK2 (0.63) | MAPK10MAPK8MAPK9PTK2MAPK3 | |
| SCHEMBL1558483 | 0.86 | MAPK10 (0.58) | MAPK10MAPK8MAPK9PTK2MAPK3 | |
| SCHEMBL691079 | 0.86 | MAPK3 (0.55) | MAPK10MAPK8MAPK9PTK2MAPK3 | |
| SCHEMBL691757 | 0.85 | MAPK3 (0.54) | MAPK10MAPK8MAPK9PTK2MAPK3 | |
| SCHEMBL691936 | 0.83 | MAPK3 (0.59) | MAPK10MAPK8MAPK9PTK2MAPK3 | |
| SCHEMBL691619 | 0.82 | MAPK3 (0.60) | MAPK10MAPK8MAPK9PTK2MAPK3 | |
| SCHEMBL691670 | 0.81 | PTK2 (0.79) | MAPK10MAPK8MAPK9PTK2MAPK3 | |
| SCHEMBL1559183 | 0.81 | MAPK3 (0.57) | MAPK10MAPK8MAPK9PTK2MAPK3 | |
| SCHEMBL12413615 | 0.79 | MAPK3 (0.68) | MAPK10MAPK8MAPK9PTK2MAPK3 | |
| SCHEMBL691569 | 0.79 | MAPK3 (0.57) | MAPK10MAPK8MAPK9PTK2MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011524411-A | — | — | 2011-09-01 | — | — | JP | claimed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | claimed |
| EP-2303861-A1 | PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| WO-2009153589-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | claimed |
| EP-2303861-B1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2014-04-23 | — | — | EP | disclosed |
| EP-2303861-B1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2014-04-23 | — | — | EP | disclosed |
| US-8569298-B2 | Pyridine compounds | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-8569298-B2 | Pyridine compounds | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-8569298-B2 | Pyridine compounds | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| EP-2303861-A1 | PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009153589-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153589-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166139-A1 | PYRIDINE COMPOUNDS | PTK2, PTK2B, PFKP | MAPK10 301/4885MAPK8 376/4885MAPK9 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.